Phase 3
Completed N=8
Glycine vs Placebo for the Schizophrenia Prodrome
Schizophrenia Prodrome
Source: ClinicalTrials.gov NCT00291226 ↗
Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Dec 2016
Primary outcomePrimary: Scale of Prodromal Symptoms Total Score — 37.8; 37.5 units on a scale
◆ Published Evidence
Established
61citations · ~5 / year
Glycine treatment of the risk syndrome for psychosis: report of two pilot studies.
Summary
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
Linked Publications
-
Glycine treatment of the risk syndrome for psychosis: report of two pilot studies.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Scale of Prodromal Symptoms Total Score |
37.8; 37.5 | — |
| PRIMARY Change in Scale of Prodromal Symptoms Total Score |
-5.8; 4.5 | — |
Eligibility Criteria
Inclusion Criteria
- meet SIPS criteria for schizophrenia prodrome
Exclusion Criteria
- history of psychosis
Data sourced from ClinicalTrials.gov (NCT00291226) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.